Nathaniel A Cohen
Overview
Explore the profile of Nathaniel A Cohen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akiyama S, Cohen N, Ollech J, Traboulsi C, Rodriguez T, Rai V, et al.
Crohns Colitis 360
. 2024 Sep;
6(3):otae045.
PMID: 39347443
Background: The modified pouchitis disease activity index (mPDAI) based on clinical symptoms and endoscopic findings is used to diagnose pouchitis, but validated instruments to monitor pouchitis are still lacking. We...
2.
Akiyama S, Ollech J, Cohen N, Traboulsi C, Rai V, Glick L, et al.
Inflamm Bowel Dis
. 2024 Jun;
31(1):63-71.
PMID: 38916136
Background: Patients with inflammatory bowel disease (IBD) who undergo proctocolectomy with ileal pouch-anal anastomosis may develop pouchitis. We previously proposed a novel endoscopic classification of pouchitis describing 7 phenotypes with...
3.
Cohen N, Choden T, Dyer E, Garcia N, Choi N, Rubin D
Dig Dis Sci
. 2024 May;
69(8):2955-2960.
PMID: 38811503
Background: The Endoscopic Healing Index (EHI) analyzes biomarkers in a patient's peripheral blood to assess mucosal healing. We aimed to characterize the effectiveness of the EHI as a predictor of...
4.
Posner H, Lombard R, Akiyama S, Cohen N, Rubin D, Dubinsky M, et al.
Inflamm Bowel Dis
. 2024 Mar;
31(1):72-76.
PMID: 38521548
Introduction: To better inform the risk of cuffitis in patients with ulcerative colitis (UC), we aimed to identify its occurrence and associated precolectomy factors in a large multicenter cohort of...
5.
Cohen N, Choi D, Garcia N, Choi N, Picker E, Krugliak Cleveland N, et al.
Dig Dis Sci
. 2023 Dec;
69(2):579-587.
PMID: 38087126
Background: Ozanimod is a first-in-class Sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of moderately to severely active ulcerative colitis (UC). Real world data describing use of ozanimod are limited....
6.
Cohen N, Weber C, Cheng J, Choi D, Garcia N, Choi N, et al.
J Crohns Colitis
. 2023 Oct;
18(4):638-641.
PMID: 37879626
Introduction: Ozanimod regulates lymphocyte egress from the spleen and lymph nodes into the systemic circulation. The histological changes which occur in the lymph nodes of patients on ozanimod is unknown....
7.
Tamir-Degabli N, Maharshak N, Cohen N
Turk J Gastroenterol
. 2023 Jun;
34(6):576-583.
PMID: 37303244
The risk of urgent bowel resection increases significantly among patients hospitalized with acute severe ulcerative colitis. In-hospital management requires quick diagnostic, therapeutic, and decision-making, combined with a multi-disciplinary approach and...
8.
Friedberg S, Choi D, Hunold T, Choi N, Garcia N, Picker E, et al.
Clin Gastroenterol Hepatol
. 2023 Mar;
21(7):1913-1923.e2.
PMID: 36898598
Background & Aims: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD),...
9.
Fenton D, Choi N, Garcia N, Dyer E, Cohen N, Rubin D
Crohns Colitis 360
. 2023 Feb;
4(4):otac042.
PMID: 36778515
Background: Fecal calprotectin (Fcal) is a noninvasive, inexpensive biomarker of disease activity. However, patient compliance with this test is variable and incompletely described. We assessed compliance rates with Fcal tests...
10.
Akiyama S, Cohen N, Kayal M, Dubinsky M, Colombel J, Rubin D
Inflamm Bowel Dis
. 2023 Feb;
29(9):1504-1507.
PMID: 36745039
No abstract available.